.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKinsey
Accenture
Chubb
Covington
Daiichi Sankyo
Fuji
Boehringer Ingelheim
Farmers Insurance

Generated: June 28, 2017

DrugPatentWatch Database Preview

Eribulin mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for eribulin mesylate and what is the scope of eribulin mesylate patent protection?

Eribulin mesylate
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eribulin mesylate has thirty-eight patent family members in twenty-one countries.

One supplier is listed for this compound.

Summary for Generic Name: eribulin mesylate

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list559
Drug Prices:see low prices
DailyMed Link:eribulin mesylate at DailyMed

Pharmacology for Ingredient: eribulin mesylate

Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes6,469,182► Subscribe ► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes7,470,720► SubscribeY ► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes8,097,648► Subscribe ► Subscribe
Eisai Inc
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes6,214,865► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: eribulin mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,365,759 Intermediate compounds for preparing macrocylcic analogs► Subscribe
8,148,554Methods and compositions for use in treating cancer► Subscribe
6,653,341 Methods and compositions for use in treating cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: eribulin mesylate

Country Document Number Estimated Expiration
Hungary227912► Subscribe
Norway2011018► Subscribe
South Korea100798600► Subscribe
Germany69943296► Subscribe
New Zealand508597► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ERIBULIN MESYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1087960/01Switzerland► SubscribePRODUCT NAME: ERIBULIN; REGISTRATION NO/DATE: SWISSMEDIC 59489 20110513
2011 00022Denmark► Subscribe
C026/2011Ireland► SubscribeSPC026/2011: 20111128, EXPIRES: 20240615
854Luxembourg► Subscribe91854, EXPIRES: 20240616
4Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Queensland Health
AstraZeneca
Argus Health
US Army
Novartis
Mallinckrodt
McKinsey
Julphar
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot